Skip to content

Study · Not a test of the peptide alone · 2023

8 results

Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.

Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M

Metabolism: clinical and experimental16 Oct 2023Cited by 55 (Europe PMC)

PMID37852529 (opens in a new tab)DOI10.1016/j.metabol.2023.155710 (opens in a new tab)PepBankPUB-37852529
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Orforglipron.

  1. 01HumanNot a test of Orforglipron aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, pooled orforglipron and danuglipron reduced HbA1c versus controls.

    In plain wordsIn patients with diabetes, pooled orforglipron and danuglipron reduced HbA1c more than controls.

    Peptide
    Orforglipron
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c mean difference
    −1.03%
    pooled drugs versus controls
    95% confidence interval for HbA1c mean difference
    −1.29 to −0.77%
    pooled orforglipron and danuglipron versus controls, type 2 diabetes
    P value for HbA1c mean difference
    < 0.001 P value
    pooled orforglipron and danuglipron versus controls, type 2 diabetes

    Source sentences

    Summary
    Novel GLP-1RAs led to significant reduction in HbA1c in patients with T2DM compared to controls (MD = -1.03 %; 95 % CI = [-1.29, -0.77]; P < 0.001).
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  2. 02HumanNot a test of Orforglipron aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, pooled orforglipron and danuglipron reduced weight versus controls, with a mean difference of -3.26 kg.

    In plain wordsIn patients with diabetes, pooled orforglipron and danuglipron reduced weight more than controls.

    Peptide
    Orforglipron
    Outcome
    DecreaseWeight in type 2 diabetes
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight mean difference
    −3.26 kg
    type 2 diabetes
    95% confidence interval for body weight mean difference
    −4.79 to −1.72 kg
    pooled orforglipron and danuglipron versus controls, type 2 diabetes
    P value for body weight mean difference
    < 0.001 P value
    pooled orforglipron and danuglipron versus controls, type 2 diabetes

    Source sentences

    Summary
    A significantly greater weight reduction was also noted both in patients with T2DM or obesity compared to controls (MD = -3.26 kg; 95 % CI = [-4.79, -1.72]; P < 0.001 and MD = -7.52 kg; 95 % CI = [-14.63, -0.41]; P = 0.038, respectively; P for subgroup differences = 0.25).
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  3. 03HumanNot a test of Orforglipron aloneSystematic reviewEfficacy outcome

    In patients with obesity, pooled orforglipron and danuglipron reduced weight versus controls, with a mean difference of -7.52 kg.

    In plain wordsIn patients with obesity, pooled orforglipron and danuglipron reduced weight more than controls.

    Peptide
    Orforglipron
    Outcome
    DecreaseWeight in obesity
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight mean difference
    −7.52 kg
    obesity
    95% confidence interval for body weight mean difference
    −14.63 to −0.41 kg
    pooled orforglipron and danuglipron versus controls, obesity
    P value for body weight mean difference
    0.038 P value
    pooled orforglipron and danuglipron versus controls, obesity

    Source sentences

    Summary
    A significantly greater weight reduction was also noted both in patients with T2DM or obesity compared to controls (MD = -3.26 kg; 95 % CI = [-4.79, -1.72]; P < 0.001 and MD = -7.52 kg; 95 % CI = [-14.63, -0.41]; P = 0.038, respectively; P for subgroup differences = 0.25).
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  4. 04HumanNot a test of Orforglipron aloneSystematic reviewEfficacy outcome

    For pooled orforglipron and danuglipron, weight reduction did not differ significantly between type 2 diabetes and obesity subgroups.

    In plain wordsFor pooled orforglipron and danuglipron, weight reduction did not differ significantly between diabetes and obesity groups.

    Peptide
    Orforglipron
    Outcome
    No significant changeWeight reduction subgroup difference
    Study

    n: not reported in source

    Comparator
    Type 2 diabetes versus obesity subgroups
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    P for subgroup differences
    0.25 P value
    type 2 diabetes versus obesity subgroups

    Source sentences

    Summary
    A significantly greater weight reduction was also noted both in patients with T2DM or obesity compared to controls (MD = -3.26 kg; 95 % CI = [-4.79, -1.72]; P < 0.001 and MD = -7.52 kg; 95 % CI = [-14.63, -0.41]; P = 0.038, respectively; P for subgroup differences = 0.25).
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  5. 05HumanNot a test of Orforglipron aloneSystematic reviewSafety outcome

    In the pooled human trials, orforglipron and danuglipron did not significantly change severe hypoglycemia odds versus controls.

    In plain wordsIn human trials, pooled orforglipron and danuglipron did not significantly change severe low blood sugar odds versus controls.

    Peptide
    Orforglipron
    Outcome
    No significant changeSevere hypoglycemia
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Odds ratio
    0.34 ratio
    severe hypoglycemia
    95% confidence interval for odds ratio
    0.09 to 1.31 ratio
    Severe hypoglycemia with pooled orforglipron and danuglipron versus controls
    P value for Severe hypoglycemia comparison
    0.11 unitless
    Severe hypoglycemia with pooled orforglipron and danuglipron versus controls

    Source sentences

    Summary
    Regarding safety, novel GLP-1RAs showed a neutral effect on the odds of severe hypoglycemia or serious adverse events (OR = 0.34; 95 % CI = [0.09, 1.31]; P = 0.11 and OR = 0.95; 95 % CI = [0.39, 2.34]; P = 0.91, respectively)
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  6. 06HumanNot a test of Orforglipron aloneSystematic reviewSafety outcome

    In the pooled human trials, orforglipron and danuglipron did not significantly change serious adverse event odds versus controls.

    In plain wordsIn human trials, pooled orforglipron and danuglipron did not significantly change serious adverse event odds versus controls.

    Peptide
    Orforglipron
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Adverse events · Whole body

    Measurements

    Odds ratio
    0.95 ratio
    serious adverse events
    95% confidence interval for odds ratio
    0.39 to 2.34 ratio
    Serious adverse events with pooled orforglipron and danuglipron versus controls
    P value for Serious adverse events comparison
    0.91 unitless
    Serious adverse events with pooled orforglipron and danuglipron versus controls

    Source sentences

    Summary
    Regarding safety, novel GLP-1RAs showed a neutral effect on the odds of severe hypoglycemia or serious adverse events (OR = 0.34; 95 % CI = [0.09, 1.31]; P = 0.11 and OR = 0.95; 95 % CI = [0.39, 2.34]; P = 0.91, respectively)
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  7. 07HumanNot a test of Orforglipron aloneSystematic reviewSafety outcome

    In the pooled human trials, orforglipron and danuglipron increased gastrointestinal treatment-emergent adverse event odds versus controls.

    In plain wordsIn human trials, pooled orforglipron and danuglipron increased digestive adverse event odds versus controls.

    Peptide
    Orforglipron
    Outcome
    IncreaseGastrointestinal treatment-emergent adverse events
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Odds ratio
    2.57 ratio
    gastrointestinal adverse events
    95% confidence interval for odds ratio
    1.49 to 4.42 ratio
    Gastrointestinal treatment-emergent adverse events with pooled orforglipron and danuglipron versus controls
    P value for Gastrointestinal treatment-emergent adverse events comparison
    < 0.001 unitless
    Gastrointestinal treatment-emergent adverse events with pooled orforglipron and danuglipron versus controls

    Source sentences

    Summary
    and significantly higher odds of gastrointestinal, treatment-emergent adverse events (OR = 2.57; 95 % CI = [1.49, 4.42]; P < 0.001)
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  8. 08HumanNot a test of Orforglipron aloneSystematic reviewSafety outcome

    In the pooled human trials, orforglipron and danuglipron increased adverse event discontinuation odds versus controls.

    In plain wordsIn human trials, pooled orforglipron and danuglipron increased the odds of stopping treatment due to adverse events versus controls.

    Peptide
    Orforglipron
    Outcome
    IncreaseAdverse events leading to discontinuation
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Adverse events · Whole body

    Measurements

    Odds ratio
    2.89 ratio
    discontinuation due to adverse events
    95% confidence interval for odds ratio
    1.22 to 6.87 ratio
    Adverse events leading to discontinuation with pooled orforglipron and danuglipron versus controls
    P value for Adverse events leading to discontinuation comparison
    0.016 unitless
    Adverse events leading to discontinuation with pooled orforglipron and danuglipron versus controls

    Source sentences

    Summary
    and adverse events leading to discontinuation (OR = 2.89; 95 % CI = [1.22, 6.87]; P = 0.016).
    2 context sentences
    Summary · context
    The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatmen…
    Summary · context
    Evidence was pooled with random effects meta-analysis.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.